Clinical Trials Logo

Filter by:
NCT ID: NCT04216693 Withdrawn - Clinical trials for Nonalcoholic Steatohepatitis

Digoxin for Patients With Non-alcoholic Steatohepatitis (NASH)

Start date: June 1, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess if digoxin is safe and efficacious in treating patients with non-alcoholic steatohepatitis (NASH) within the approved target range of 0.7 to 1 ng/ml.

NCT ID: NCT04215549 Withdrawn - Clinical trials for Obsessive-Compulsive Disorder

The Cost of Obsessive-compulsive Disorder (OCD) in China

OCD
Start date: January 2, 2020
Phase:
Study type: Observational

The purpose of this study is to estimate the cost of obsessive-compulsive disorder in China based on the prevalence rate from a social perspective.

NCT ID: NCT04199520 Withdrawn - Clinical trials for Stage IV Breast Cancer

Compare the Efficacy of Surgery Combined With Systemic Therapy and Pure Systemic Therapy in Breast Cancer Patients

Start date: April 15, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the effect of primary resection combined with systemic therapy and pure systemic therapy on the overall survival of patients with stage Ⅳ breast cancer.

NCT ID: NCT04160559 Withdrawn - Clinical trials for Non-small Cell Lung Cancer

Green Tea Combined With Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer

Start date: January 11, 2020
Phase: N/A
Study type: Interventional

Patients with non-small cell lung cancer who met the inclusion and exclusion criteria were screened and randomly divided into control group and experimental group. Control group: chemotherapy plus water ,test group: chemotherapy plus green tea. Primary endpoint: Assessment of changes in quality of life (QOL) after chemotherapy according to FACT-L (4th edition). A clinically significant change in the quality of life of lung cancer was defined as a FACT-L score change of ≥6 points from baseline, with <6 points defined as no clinically significant changes;

NCT ID: NCT04150666 Withdrawn - Renal Insufficiency Clinical Trials

The Water Intake Trail and Primary Aldosteronism Postoperation(WIT-PAP)

Start date: December 1, 2019
Phase: N/A
Study type: Interventional

To investigate whether increasing water intake has renal protective effect on PA patients after surgical treatment.

NCT ID: NCT04126044 Withdrawn - Pharmacokinetics Clinical Trials

A SINGLE-DOSE, 2-ARM, PHARMACOKINETIC STUDY OF PF-06439535 (CN) AND EUROPEAN UNION SOURCED BEVACIZUMAB IN CHINESE HEALTHY MALE VOLUNTEERS

Start date: January 22, 2021
Phase: Phase 1
Study type: Interventional

This is a double-blind, randomized (1:1), parallel group, single dose, 2-arm, comparative PK study of PF-06439535 (CN) and bevacizumab-EU administered intravenously to Chinese healthy male volunteers. Approximately 66 subjects will be enrolled to ensure that at least 58 subjects (29 per arm) complete the study procedures and have evaluable PK data. The study will be conducted at 1 center in China.

NCT ID: NCT04094766 Withdrawn - Clinical trials for Refractory B Acute Lymphoblastic Leukemia

Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia

Start date: August 1, 2017
Phase: Phase 1
Study type: Interventional

This is a single arm, open-label, dose escalation clinical study to evaluate the safety and efficacy of infusion of dual specificity CD19 and CD22 CAR-T cells in patients with relapsed and refractory acute B lymphoblastic leukemia.

NCT ID: NCT04082715 Withdrawn - Chronic Back Pain Clinical Trials

Transition From Acute to Chronic Back Pain : Effect of L-dopa,Gender,and Associated Brain Plasticity

Start date: October 2019
Phase: Phase 2
Study type: Interventional

This is a 6-month double-blinded, randomized, placebo-controlled clinical trial of pharmacological treatment (carbidopa/levodopa and celecoxib) for acute/subacute back pain. All eligible patients will be randomly assigned to 3 different group and receive a 12-week treatment of "carbidopa/levodopa+celecoxib ", of "placebo+celecoxib", and of "placebo+placebo". In addition, all participants will be MRI-scanned twice and assessed daily with a mobile app for pan, mood, and behavior.

NCT ID: NCT04067102 Withdrawn - Clinical trials for Triple Negative Breast Cancer

Nab-paclitaxel Based Regimens VS Paclitaxel Based Regimens in Neoadjuvant Treatment for TNBC

Start date: May 10, 2019
Phase: N/A
Study type: Interventional

To evaluate the efficacy and safety of P nab-paclitaxel combined with carboplatin versus paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide in the neoadjuvant treatment of triple negative breast cancer.

NCT ID: NCT04060888 Withdrawn - Clinical trials for Lupus Erythematosus, Systemic

A Study of Ustekinumab in Chinese Participants With Active Systemic Lupus Erythematosus

Start date: July 14, 2020
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of ustekinumab in Chinese participants with active systemic lupus erythematosus (SLE) who have not adequately responded to one or more standard-of-care treatments.